6533b857fe1ef96bd12b50f6
RESEARCH PRODUCT
A case of Waldenstroem's disease with a monoclonal IgM antiphospholipid antibody
Jürgen SchölmerichKarl J. LacknerMartin VogelhuberReinhard AndreesenPhilipp Von Landenbergsubject
Pathologymedicine.medical_specialtyImmunologymedicine.disease_causeSerologyAutoimmunityImmunoglobulin kappa-ChainsRheumatologyimmune system diseasesAntiphospholipid syndromemedicineHumansImmunology and AllergyGlycoproteinsLupus anticoagulantbiologybusiness.industryAutoantibodyWaldenstrom macroglobulinemiaMiddle Agedmedicine.diseaseTreatment OutcomeImmunoglobulin Mbeta 2-Glycoprotein ILupus Coagulation InhibitorImmunologyMonoclonalAntibodies Antiphospholipidbiology.proteinFemaleWaldenstrom MacroglobulinemiaAntibodybusinessParaproteinsdescription
The antiphospholipid syndrome (APS) was described in 1983 as a clinical entity characterized by venous and arterial thrombosis, thrombocytopenia, and recurrent fetal loss. The serological markers of APS are antiphospholipid antibodies (APLA) directed mainly against anionic phospholipids, usually cardiolipin but also phosphatidylserine. Some APLA exhibit lupus anticoagulant activity. Monoclonal gammopathy sometimes occurs with the presence of autoantibodies. In this paper, we describe a patient with the diagnosis of immunocytoma with an IgM, kappa paraprotein with apparent specificity against anionic phospholipids, and lupus anticoagulant activity, but no clinical signs of APS. We describe in this patient the presence of a high titer of monoclonal APLA, which does apparently not induce the clinical symptoms of APS. This might be indicative for the presence of pathogenic and nonpathogenic antiphospholipid antibodies.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2002-01-25 | Rheumatology International |